Core Viewpoint - The article highlights the significant growth and market dominance of Suhexiang Wan, a traditional Chinese medicine, in the cardiovascular disease prevention and treatment sector, driven by policy support and modern clinical research [2][3]. Group 1: Market Performance - Suhexiang Wan's sales in urban public hospitals increased from 42.08 million yuan in 2020 to 558 million yuan in 2023, while retail sales in urban pharmacies rose from 232,000 yuan to 8.2 million yuan by 2024 [1]. - In the first half of 2024, Lei Yun Shang's Suhexiang Wan held a market share of approximately 75.15% in urban public medical institutions, with a retail growth rate of 236%, significantly outpacing competitors like Pian Zai Huang and Gui Ling Ji [1][3]. Group 2: Clinical and Retail Insights - Suhexiang Wan has been widely applied in clinical settings, covering nearly 3,000 hospitals and demonstrating effectiveness in emergency cases and cardiovascular disease prevention [4]. - The product's clear efficacy and modern adaptation have contributed to its retail success, contrasting with the slower growth of other traditional medicines like An Gong Niu Huang Wan and Gui Ling Ji, which saw declines in sales [5][6]. Group 3: Policy and Industry Trends - The Chinese government has intensified support for traditional Chinese medicine, with the "14th Five-Year Plan for Traditional Chinese Medicine Development" emphasizing the development and clinical application of classic formulas like Suhexiang Wan [6]. - The demand for cardiovascular health products is surging, with 81.7% of respondents in a health survey willing to invest more in health, indicating a growing market for traditional Chinese medicine [6][7]. Group 4: Competitive Landscape - The market for cardiovascular traditional Chinese medicine has expanded significantly, with total sales increasing from 5.216 billion yuan in 2017 to 10.083 billion yuan in 2024, nearly doubling [3]. - Suhexiang Wan's competitive edge is reinforced by its strong clinical evidence and market positioning, as it continues to capture a larger share of the growing demand for cardiovascular treatments [8].